Zhu Nemin, Rowe Neal E, Martin Paul R, Luke Sean S, Mcgregor Thomas B, Myslik Frank, Mcalister Vivian C, Sener Alp, Luke Patrick P
Western University Schulich School of Medicine and Dentistry, London, ON; Canada.
Department of Surgery, University of Ottawa, Ottawa, ON; Canada.
Can Urol Assoc J. 2018 Jun;12(6):188-192. doi: 10.5489/cuaj.4702. Epub 2018 Feb 23.
We sought to determine whether protocol biopsies could be used to guide treatment and improve outcomes in simultaneous pancreas-kidney (SPK) patients.
Between 2004 and 2013, protocol biopsies were performed on SPK patients at 3-6 months and one year post-transplant. Maintenance immunosuppression consisted of a calcineurin inhibitor, anti-proliferative agent, and corticosteroid. Corticosteroid was withdrawn in negative early biopsies, maintained in subclinical/ borderline biopsies, and increased if Banff IB or greater rejection was identified. Endpoints included presence of interstitial fibrosis and tubular atrophy on biopsy at one year (IF/TA), rejection episodes, and renal and pancreas function at five years' followup.
Forty-one SPK transplant patients were reviewed and a total of 75 protocol biopsies were identified. On early biopsy, 51% had negative biopsies, 44% had borderline rejection, and 5% had subclinical rejection. Renal and pancreas function were not significantly different at one, two, and five years post-transplant between negative vs. borderline early biopsy patients. No difference in the degree of IF/TA was found between these two groups.
To our knowledge, this is the first study to evaluate protocol biopsies as an investigative tool prior to steroid withdrawal in SPK patients. Our study suggests that there are no detrimental functional or histological effects at five years post-transplant, despite weaning steroids in the negative biopsy group.
我们试图确定方案活检是否可用于指导同时进行胰腺-肾脏移植(SPK)患者的治疗并改善其预后。
在2004年至2013年期间,对SPK患者在移植后3至6个月及1年时进行方案活检。维持性免疫抑制包括钙调神经磷酸酶抑制剂、抗增殖药物和皮质类固醇。早期活检结果为阴性时停用皮质类固醇,活检结果为亚临床/临界状态时维持使用,若发现Banff IB级或更高级别的排斥反应则增加皮质类固醇剂量。观察终点包括移植1年时活检的间质纤维化和肾小管萎缩(IF/TA)情况、排斥反应发作次数以及5年随访时的肾脏和胰腺功能。
对41例SPK移植患者进行了回顾,共确定了75次方案活检。早期活检时,51%的患者活检结果为阴性,44%为临界排斥,5%为亚临床排斥。移植1年、2年和5年时,早期活检结果为阴性与临界的患者之间,肾脏和胰腺功能无显著差异。两组之间IF/TA程度无差异。
据我们所知,这是第一项在SPK患者停用类固醇之前评估方案活检作为一种研究工具的研究。我们的研究表明,尽管阴性活检组停用了类固醇,但移植后5年时没有出现有害的功能或组织学影响。